Biotech & Life Sciences

Simultaneously loosening access to unproven peptides and raising the bar for one-patient gene therapies, the FDA is making opposite bets on what access should mean.

An asthma drug approved in 2005 is showing unexpected promise for treating food allergies — and the data on severe reactions is surprisingly clean.

The failed melanoma vaccine showed a 16.6-month benefit in one subgroup but missed its primary endpoint. Now a bankruptcy trustee is selling the IP — and the price will tell us if the field sees salvage value in a statistical miss.

In 71 IPF patients over 12 weeks, an AI-designed drug produced a 98.4 mL lung function improvement — real signal or noise? The Phase III will decide, but Insilico just signed a $2.75B Lilly deal before a single Phase III patient was enrolled.

Patients who stay on Novo Nordisk's new Wegovy subscription for a full year pay $2,988 versus $4,188 at standard monthly rates. The problem: most patients quit within 12 months.

ORIC picked a sensible dose for its prostate cancer drug. The market dropped the stock 27% because the real question is why the company chose darolutamide as its combination partner — and what Pfizer found with a similar drug first.

The condition affecting one in eight women is getting a new name because its ovaries dont have cysts. But renaming a womens condition as metabolic may fix the framing without fixing the neglect.

A clinical trial at MGH is testing whether what happens before and after a ketamine session matters as much as the drug itself. If it does, the entire psychedelic medicine industry gets a new playbook.

NIH Director Jay Bhattacharya cited Vannevar Bush at CPAC to argue for restructuring the agency. The man who designed NIH autonomy also wrote the document Bhattacharya is using to dismantle it.

Every human cell holds two meters of DNA — and it never stops moving. A new Salk paper finds the genome folds and unfolds at a pace that determines whether genes are on or off, linking disrupted motion to cancer and autism.

Kratom poison control calls surged 1,200% over a decade, reaching a record 3,434 in 2025. The driver is not the plant itself but a concentrated 7-OH derivative that emerged in late 2023, now linked to the worst outcomes.